March 14, 2022Open Access

Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: a prospective study

Key Points

Key points are not available for this paper at this time.

Abstract

The registered name of the trial is "Prospective clinical study of sintilimab combined with chemotherapy for neoadjuvant therapy in locally advanced gastric cancer". Its Current Controlled Trials number is ChiCTR2000030414. Its date of registration is 01/03/2020.

AI에게 질문

Bookmark

View Full Paper

Cite This Study

Ding et al. (Mon,) studied this question.

synapsesocial.com/papers/69daa2560d540cafc58397df https://doi.org/https://doi.org/10.1186/s12876-022-02199-9

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

AI에게 질문

Bookmark

View Full Paper